[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Lozano-Ondoua AN, Wright C, Vardanyan A, King T, Largent-Milnes TM, Nelson M, Jimenez-Andrade JM, Mantyh PW, Vanderah TW: A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Life Sci; 2010 Apr 24;86(17-18):646-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MAIN METHODS: A murine bone cancer model was used in which osteolytic sarcoma cells were injected into the intramedullary space of the distal end of the femur.
  • KEY FINDINGS: Osteolytic sarcoma within the femur produced spontaneous and touch evoked behavioral signs of pain within the tumor-bearing limb.
  • SIGNIFICANCE: These findings suggest a novel therapy for cancer-induced bone pain, bone loss and bone fracture while lacking many unwanted side effects seen with current treatments for bone cancer pain.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroscience. 2005;135(1):235-45 [16084654.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):211-26 [16169466.001]
  • [Cites] Science. 2005 Oct 14;310(5746):329-32 [16224028.001]
  • [Cites] Hum Mol Genet. 2005 Nov 15;14(22):3389-96 [16204352.001]
  • [Cites] Eur J Pharmacol. 2005 Dec 19;527(1-3):172-4 [16316653.001]
  • [Cites] J Immunol. 2006 Jan 1;176(1):284-90 [16365420.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):696-701 [16407142.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] Brain Res. 2006 Feb 3;1071(1):10-23 [16472786.001]
  • [Cites] Methods Mol Med. 2006;123:291-8 [16506415.001]
  • [Cites] Eur J Neurosci. 2006 Mar;23(6):1530-8 [16553616.001]
  • [Cites] Pain. 2006 May;122(1-2):36-42 [16563625.001]
  • [Cites] Oncol Rep. 2006 Jun;15(6):1477-84 [16685382.001]
  • [Cites] Curr Pharm Des. 2006;12(24):3135-46 [16918439.001]
  • [Cites] Pharmacol Ther. 2006 Oct;112(1):116-38 [16730375.001]
  • [Cites] Br J Pharmacol. 2006 Sep;149(2):145-54 [16894349.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s [17062708.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Sep;25(3):365-72 [17167977.001]
  • [Cites] Calcif Tissue Int. 2007 Jan;80(1):50-9 [17205329.001]
  • [Cites] J Neurosci. 1999 Dec 15;19(24):10886-97 [10594070.001]
  • [Cites] Breast Cancer Res Treat. 2000 Feb;59(3):271-8 [10832597.001]
  • [Cites] J Neurosci. 2000 Sep 15;20(18):7074-9 [10995854.001]
  • [Cites] Chem Phys Lipids. 2000 Nov;108(1-2):89-106 [11106784.001]
  • [Cites] J Neurosci. 2001 Jan 1;21(1):279-86 [11150345.001]
  • [Cites] Prog Neurobiol. 2001 Apr;63(5):569-611 [11164622.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4038-47 [11358823.001]
  • [Cites] Pain. 2001 Sep;93(3):239-45 [11514083.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):514-21 [11736931.001]
  • [Cites] Int Immunopharmacol. 2002 Jan;2(1):69-82 [11789671.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):201-9 [11990856.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):177-89 [12463738.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Curr Opin Pharmacol. 2003 Feb;3(1):62-7 [12550743.001]
  • [Cites] Nature. 2003 May 15;423(6937):337-42 [12748652.001]
  • [Cites] Eur J Neurosci. 2003 Jun;17(12):2750-4 [12823482.001]
  • [Cites] Chem Immunol Allergy. 2003;83:167-81 [12947984.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10529-33 [12917492.001]
  • [Cites] J Leukoc Biol. 2003 Oct;74(4):486-96 [12960289.001]
  • [Cites] Novartis Found Symp. 2004;256:158-68; discussion 168-72, 259-69 [15027489.001]
  • [Cites] Trends Immunol. 2004 May;25(5):235-41 [15099563.001]
  • [Cites] J Neurobiol. 2004 Oct;61(1):149-60 [15362158.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1980;20:441-62 [7387124.001]
  • [Cites] Nature. 1986 Feb 6-12;319(6053):516-8 [3511389.001]
  • [Cites] Phytother Res. 2007 Feb;21(2):99-112 [17106868.001]
  • [Cites] Curr Med Chem. 2007;14(8):917-36 [17430144.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4507-13 [17483367.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5064-6 [17545580.001]
  • [Cites] Curr Opin Oncol. 2007 Jul;19(4):308-14 [17545792.001]
  • [Cites] Br J Pharmacol. 2007 Aug;151(7):1061-70 [17549048.001]
  • [Cites] Pain. 2007 Nov;132(1-2):154-68 [17706870.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2210-8 [17660390.001]
  • [Cites] Exp Cell Res. 2008 Jan 1;314(1):173-83 [17976581.001]
  • [Cites] J Cell Physiol. 2008 Mar;214(3):714-20 [17786950.001]
  • [Cites] Breast Cancer Res. 2007;9(4):212 [17705880.001]
  • [Cites] Br J Pharmacol. 2008 Jan;153(2):319-34 [17994113.001]
  • [Cites] Br J Pharmacol. 2008 Jan;153(2):182-8 [18071301.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):11-8 [18066650.001]
  • [Cites] Eur J Pharmacol. 2008 Mar 31;583(1):56-61 [18279850.001]
  • [Cites] Anesthesiology. 2008 Apr;108(4):722-34 [18362605.001]
  • [Cites] J Neurosci. 2008 May 14;28(20):5189-94 [18480275.001]
  • [Cites] Cancer Treat Rev. 2008 Oct;34(6):527-38 [18472222.001]
  • [Cites] Synapse. 2008 Dec;62(12):944-9 [18798269.001]
  • [Cites] Drugs Today (Barc). 2008 Sep;44(9):693-709 [19137124.001]
  • [Cites] Br J Pharmacol. 2009 Sep;158(1):382-91 [19552692.001]
  • [Cites] Neurosci Lett. 2006 Mar 27;396(2):113-6 [16356641.001]
  • [Cites] Endocrinology. 1987 Nov;121(5):1596-604 [3665833.001]
  • [Cites] J Bone Miner Res. 1987 Dec;2(6):559-65 [3502684.001]
  • [Cites] J Immunol. 1992 Feb 1;148(3):788-94 [1309841.001]
  • [Cites] J Pathol. 1994 Mar;172(3):229-35 [8195926.001]
  • [Cites] J Neurosci Methods. 1994 Jul;53(1):55-63 [7990513.001]
  • [Cites] FEBS Lett. 1995 Aug 7;369(2-3):177-82 [7544292.001]
  • [Cites] Eur J Biochem. 1995 Aug 15;232(1):54-61 [7556170.001]
  • [Cites] Pain. 1997 Jan;69(1-2):1-18 [9060007.001]
  • [Cites] Eur J Cancer. 1998 Feb;34(2):210-3 [9741323.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1382-97 [10364156.001]
  • [Cites] Eur J Pharmacol. 1999 Jul 14;377(1):117-25 [10448934.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5C):3335-42 [15515429.001]
  • [Cites] Clin Exp Allergy. 2004 Nov;34(11):1660-4 [15544587.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):3093-8 [15705714.001]
  • [Cites] J Pain Symptom Manage. 2005 May;29(5 Suppl):S32-46 [15907645.001]
  • [Cites] Oncol Rep. 2005 Aug;14(2):425-31 [16012726.001]
  • [Cites] Nat Med. 2005 Jul;11(7):774-9 [15908955.001]
  • [Cites] Eur J Neurosci. 2005 Jul;22(2):371-9 [16045490.001]
  • (PMID = 20176037.001).
  • [ISSN] 1879-0631
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA142115-01A1; United States / NCI NIH HHS / CA / R01 CA142115; United States / NCI NIH HHS / CA / R01 CA142115-01A1
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / AM 1241; 0 / Analgesics; 0 / Cannabinoids; 0 / Receptor, Cannabinoid, CB2
  • [Other-IDs] NLM/ NIHMS196861; NLM/ PMC2871326
  •  go-up   go-down


2. King T, Vardanyan A, Majuta L, Melemedjian O, Nagle R, Cress AE, Vanderah TW, Lai J, Porreca F: Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. Pain; 2007 Nov;132(1-2):154-68
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer.
  • A model of bone cancer pain in which the progression of cancer pain and bone destruction is tightly controlled was used to evaluate the effects of sustained morphine treatment.
  • SP and CGRP positive DRG cells did not differ between sarcoma or control mice, but were increased following morphine in both groups.
  • Morphine increased ATF-3 expression only in DRG cells of sarcoma mice.
  • Morphine did not alter tumor growth in vitro or tumor burden in vivo but accelerated sarcoma-induced bone destruction and doubled the incidence of spontaneous fracture in a dose- and naloxone-sensitive manner.
  • Morphine increased osteoclast activity and upregulated IL-1 beta within the femurs of sarcoma-treated mice suggesting enhancement of sarcoma-induced osteolysis.
  • Morphine treatment may result in "add-on" mechanisms of pain beyond those engaged by sarcoma alone.
  • While it is not known whether the present findings in this model of osteolytic sarcoma will generalize to other cancers or opioids, the data suggest a need for increased understanding of neurobiological consequences of prolonged opioid exposure which may allow improvements in the use of opiates in the effective management of cancer pain.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2005 Mar 18;328(3):728-38 [15694407.001]
  • [Cites] Exp Neurol. 2005 May;193(1):85-100 [15817267.001]
  • [Cites] Pain. 2005 May;115(1-2):128-41 [15836976.001]
  • [Cites] Pharmacol Biochem Behav. 2005 May;81(1):114-21 [15894068.001]
  • [Cites] J Med Genet. 2005 Jul;42(7):583-7 [15994880.001]
  • [Cites] Pain. 2005 Aug;116(3):276-88 [15964684.001]
  • [Cites] J Biol Chem. 2005 Aug 26;280(34):30192-200 [15961387.001]
  • [Cites] Neurosignals. 2005;14(4):194-205 [16215302.001]
  • [Cites] Tidsskr Nor Laegeforen. 2005 Oct 6;125(19):2655-8 [16215614.001]
  • [Cites] Neuropeptides. 2005 Oct;39(5):495-505 [16169076.001]
  • [Cites] J Pain Symptom Manage. 2005 Nov;30(5):485-91 [16310622.001]
  • [Cites] J Pain. 2005 Dec;6(12):837-45 [16326372.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2005 Nov;372(3):213-9 [16283255.001]
  • [Cites] J Pain. 2006 Jan;7(1):43-8 [16414554.001]
  • [Cites] J Orthop Res. 2006 Jan;24(1):29-36 [16419966.001]
  • [Cites] Neurosci Lett. 2006 Mar 20;396(1):44-9 [16343768.001]
  • [Cites] Brain Res. 2006 Jan 27;1070(1):35-44 [16409995.001]
  • [Cites] Anesthesiology. 2006 Mar;104(3):546-55 [16508403.001]
  • [Cites] Eur J Pharmacol. 2006 Mar 18;534(1-3):250-7 [16513108.001]
  • [Cites] Drug Alcohol Depend. 2006 May 20;82(3):218-23 [16229972.001]
  • [Cites] J Periodontal Res. 2006 Aug;41(4):273-9 [16827720.001]
  • [Cites] Biomaterials. 2006 Oct;27(30):5161-9 [16814378.001]
  • [Cites] Carcinogenesis. 1996 Nov;17(11):2337-41 [8968046.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1588-94 [9362426.001]
  • [Cites] Pain. 1997 Oct;73(1):37-45 [9414055.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2299-306 [9635520.001]
  • [Cites] Neuroscience. 2000;98(3):585-98 [10869852.001]
  • [Cites] Eur J Cancer. 1998 Apr;34(5):627-31 [9713265.001]
  • [Cites] Bone. 2006 Nov;39(5):985-90 [16870519.001]
  • [Cites] Cancer Metastasis Rev. 2006 Dec;25(4):541-9 [17180711.001]
  • [Cites] Osteoarthritis Cartilage. 2007 Mar;15(3):291-9 [16979913.001]
  • [Cites] J Pain Symptom Manage. 2001 Mar;21(3):255-64 [11239748.001]
  • [Cites] BMJ. 2001 May 12;322(7295):1154-8 [11348910.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4038-47 [11358823.001]
  • [Cites] Cancer Treat Rev. 2001 Jun;27(3):165-76 [11417967.001]
  • [Cites] Drugs. 2001;61(7):955-77 [11434451.001]
  • [Cites] Sports Med. 2002;32(7):459-76 [12015807.001]
  • [Cites] J Neurosci. 2002 Aug 1;22(15):6747-55 [12151554.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4491-8 [12154060.001]
  • [Cites] Pharmacol Biochem Behav. 2002 Nov;73(4):821-8 [12213527.001]
  • [Cites] Pain. 2002 Oct;99(3):397-406 [12406514.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7343-9 [12499278.001]
  • [Cites] Cancer. 2003 Feb 1;97(3 Suppl):866-73 [12548588.001]
  • [Cites] J Orthop Res. 2003 Mar;21(2):202-12 [12568950.001]
  • [Cites] Adv Exp Med Biol. 2003;521:106-16 [12617569.001]
  • [Cites] Brain Res. 2003 Apr 18;969(1-2):102-9 [12676370.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1846-52 [12702572.001]
  • [Cites] Kidney Int Suppl. 2003 Jun;(85):S2-5 [12753255.001]
  • [Cites] Oncology (Williston Park). 2003 Jun;17(6):845-57; discussion 862-3, 867 [12846127.001]
  • [Cites] Neuroreport. 2003 May 6;14(6):867-9 [12858049.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1856-66 [10547561.001]
  • [Cites] J Neurosci. 1999 Dec 15;19(24):10886-97 [10594070.001]
  • [Cites] Nat Med. 2000 May;6(5):521-8 [10802707.001]
  • [Cites] J Neurosci. 2000 Sep 15;20(18):7074-9 [10995854.001]
  • [Cites] Neuroscience. 2000;99(3):529-39 [11029544.001]
  • [Cites] J Neurosci. 2001 Jan 1;21(1):279-86 [11150345.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):587-93 [11237376.001]
  • [Cites] J Pain Symptom Manage. 2003 Aug;26(2):769-75 [12906962.001]
  • [Cites] Rheumatology (Oxford). 2004 Apr;43(4):435-41 [14762224.001]
  • [Cites] Neurosci Lett. 2004 May 6;361(1-3):184-7 [15135924.001]
  • [Cites] Clin Orthop Relat Res. 2004 Aug;(425):244-51 [15292815.001]
  • [Cites] J Neurosci. 2004 Aug 18;24(33):7353-65 [15317861.001]
  • [Cites] J Neurobiol. 2004 Oct;61(1):126-48 [15362157.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1980;20:441-62 [7387124.001]
  • [Cites] NIDA Res Monogr. 1984 Mar;49:344-50 [6434984.001]
  • [Cites] Brain Res Bull. 1986 Mar;16(3):363-7 [3708390.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 May;87(9):3294-8 [2159143.001]
  • [Cites] Pain. 1991 Apr;45(1):107-8 [1861874.001]
  • [Cites] J Pain Symptom Manage. 1991 Nov;6(8):484-6 [1720156.001]
  • [Cites] Biol Pharm Bull. 1993 Aug;16(8):762-6 [8220322.001]
  • [Cites] Pain. 1993 Oct;55(1):93-7 [8278214.001]
  • [Cites] J Neurosci Methods. 1994 Jul;53(1):55-63 [7990513.001]
  • [Cites] Cell Growth Differ. 1994 Oct;5(10):1033-40 [7848904.001]
  • [Cites] Pain. 1994 Nov;59(2):313-6 [7892029.001]
  • [Cites] Anticancer Drugs. 1995 Apr;6 Suppl 3:44-9 [7606037.001]
  • [Cites] Ugeskr Laeger. 1995 Jun 5;157(23):3307-10 [7543228.001]
  • [Cites] J Orthop Res. 1995 Nov;13(6):892-7 [8544026.001]
  • [Cites] J Orthop Res. 1996 Jan;14(1):2-6 [8618161.001]
  • [Cites] Eur J Neurosci. 1998 Feb;10(2):782-5 [9749743.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Nov 27;252(3):566-70 [9837747.001]
  • [Cites] Pain. 1999 Jan;79(1):1-13 [9928770.001]
  • [Cites] J Bone Miner Res. 1999 Mar;14(3):464-9 [10027912.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):83-94 [10068197.001]
  • [Cites] Neuroscience. 1999 Mar;89(3):631-6 [10199599.001]
  • [Cites] J Clin Invest. 2005 Feb;115(2):282-90 [15668736.001]
  • [CommentIn] Pain. 2007 Nov;132(1-2):5-7 [17854996.001]
  • (PMID = 17706870.001).
  • [ISSN] 1872-6623
  • [Journal-full-title] Pain
  • [ISO-abbreviation] Pain
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA56666; United States / NCI NIH HHS / CA / P30 CA023074; United States / NCI NIH HHS / CA / P30 CA023074-30; United States / NIDA NIH HHS / DA / R01 DA011823; United States / NCI NIH HHS / CA / P01 CA056666-110002; United States / NIDA NIH HHS / DA / DA12656; United States / NCI NIH HHS / CA / P01 CA056666; None / None / / P30 CA023074-30; United States / NCI NIH HHS / CA / CA23074; United States / NIDA NIH HHS / DA / DA11823; United States / NCI NIH HHS / CA / CA056666-110002; United States / NIDA NIH HHS / DA / R01 DA012656; United States / NIDA NIH HHS / DA / DA1643
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 76I7G6D29C / Morphine
  • [Other-IDs] NLM/ NIHMS121880; NLM/ PMC2704581
  •  go-up   go-down


3. Théoleyre S, Mori K, Cherrier B, Passuti N, Gouin F, Rédini F, Heymann D: Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer; 2005;5:123
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma.
  • BACKGROUND: Osteosarcoma is the most common type of primary bone tumor.
  • The use of aggressive chemotherapy has drastically improved the prognosis of the patients with non-metastatic osteosarcomas, however the prognosis of the patients with metastasis is still very poor.
  • Then, new and more effective treatments for curing osteosarcoma, such as immunotherapy are needed.
  • Tumor-infiltrating lymphocytes (TIL) have been involved in the control of tumor development and already assessed with success for the treatment of several cancers including melanoma.
  • While TIL represent a fascinating therapeutic approach in numerous malignant pathologies, there is few report concerning adult bone-associated tumors including osteosarcoma.
  • METHODS: Human TIL were isolated and characterized (phenotype, lytic activity) from twenty-seven patients with bone-associated tumors (osteosarcoma, Ewing's sarcoma, giant cell tumor, chondrosarcoma, plasmocytoma and bone metastases).
  • CONCLUSION: These results demonstrated that TIL therapy could be a very efficient strategy for the treatment of adult osteosarcoma.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1999 Nov;12(11):1050-6 [10574602.001]
  • [Cites] Cancer Immunol Immunother. 2006 Apr;55(4):451-8 [16034562.001]
  • [Cites] Int J Oncol. 2000 Jul;17(1):29-32 [10853014.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Jul-Aug;17(5):355-64 [10914045.001]
  • [Cites] Nature. 2001 May 17;411(6835):380-4 [11357146.001]
  • [Cites] J Orthop Res. 2001 May;19(3):346-51 [11398844.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):963-70 [11549589.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14565-70 [11734652.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3950-62 [11751487.001]
  • [Cites] Cancer Immunol Immunother. 2002 Nov;51(10):539-46 [12384805.001]
  • [Cites] J Immunother. 2003 Jul-Aug;26(4):332-42 [12843795.001]
  • [Cites] Eur J Surg Oncol. 2004 Feb;30(1):53-7 [14736523.001]
  • [Cites] Intern Med. 2004 Apr;43(4):323-6 [15168777.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5442-8 [15289353.001]
  • [Cites] Cancer. 1976 Jan;37(1):1-11 [1082364.001]
  • [Cites] Int J Cancer. 1977 Jul 15;20(1):112-9 [269099.001]
  • [Cites] Science. 1986 Sep 19;233(4770):1318-21 [3489291.001]
  • [Cites] J Biol Response Mod. 1990 Apr;9(2):149-59 [1971302.001]
  • [Cites] Eur J Immunol. 1991 Jun;21(6):1403-10 [1904359.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 3;83(13):932-7 [2067036.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):8-14 [1884563.001]
  • [Cites] Cancer Immunol Immunother. 1992;34(4):241-51 [1311218.001]
  • [Cites] Cancer Immunol Immunother. 1994 May;38(5):332-8 [8162615.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66 [8028037.001]
  • [Cites] Immunol Rev. 1995 Jun;145:167-77 [7590825.001]
  • [Cites] Ann Surg Oncol. 1996 Nov;3(6):580-7 [8915492.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):76-84 [8996127.001]
  • [Cites] J Orthop Res. 1997 Jan;15(1):128-32 [9066537.001]
  • [Cites] Br J Urol. 1997 Oct;80(4):543-7 [9352689.001]
  • [Cites] Pathol Res Pract. 1998;194(10):679-84 [9820863.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2A):1137-42 [10368665.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):721-6 [10505031.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Dec;19(6):730-7 [15665620.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2591-601 [15728465.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):2026-34 [15753403.001]
  • [Cites] J Exp Med. 2005 Mar 7;201(5):779-91 [15753211.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2457-64 [15781662.001]
  • [Cites] J Immunother. 2005 May-Jun;28(3):258-67 [15838383.001]
  • [Cites] J Immunol. 2005 May 15;174(10):5959-67 [15879088.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3998-4004 [15899788.001]
  • [Cites] Bone. 2005 Jul;37(1):74-86 [15894525.001]
  • [Cites] Eur J Immunol. 2005 Jun;35(6):1754-63 [15902685.001]
  • [Cites] Oncol Rep. 2005 Sep;14(3):763-9 [16077989.001]
  • [Cites] Tumori. 2000 Jan-Feb;86(1):46-52 [10778766.001]
  • (PMID = 16188028.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1262697
  •  go-up   go-down


Advertisement
4. Zhou Z, Guan H, Duan X, Kleinerman ES: Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer; 2005 Oct 15;104(8):1713-20
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma.
  • BACKGROUND: Zoledronic acid has been shown to be effective in the treatment of osteoporosis, hypercalcemia, and metastatic bone tumors.
  • Intratibia injection of TC71 cells resulted in an osteolytic bone tumor.
  • RESULTS: Zoledronic acid induced apoptosis in TC71 human Ewing sarcoma cells and inhibited cell proliferation.
  • Five weeks after injection, 89% of mice in the control group developed osteolytic bone tumors.
  • By contrast, 44% of mice treated with zoledronic acid developed bone tumors.
  • The most effective treatment was zoledronic acid plus paclitaxel.
  • Tumor incidence in the combination therapy group was only 22%.
  • There was a decrease in TRAP-positive osteoclasts in tumor tissues from zoledronic acid-treated animals compared to control animals.
  • CONCLUSIONS: These results suggest that zoledronic acid induces apoptosis and inhibits primary bone tumor growth in Ewing sarcoma through a mechanism involving the up-regulation of osteoprotegerin.
  • Zoledronic acid may provide a novel therapeutic approach for the treatment of patients with Ewing sarcoma.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Bone Neoplasms / drug therapy. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Sarcoma, Ewing / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Agents, Phytogenic / therapeutic use. Apoptosis / drug effects. Cell Proliferation / drug effects. Drug Therapy, Combination. Enzyme-Linked Immunosorbent Assay. Glycoproteins / metabolism. Humans. Immunoenzyme Techniques. Mice. Mice, Nude. Osteoclasts / cytology. Osteoclasts / drug effects. Osteoclasts / metabolism. Osteoprotegerin. Paclitaxel / therapeutic use. Receptors, Cytoplasmic and Nuclear / metabolism. Receptors, Tumor Necrosis Factor / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16121404.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 82606; United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Glycoproteins; 0 / Imidazoles; 0 / Osteoprotegerin; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Tumor Necrosis Factor; 0 / TNFRSF11B protein, human; 0 / Tnfrsf11b protein, mouse; 6XC1PAD3KF / zoledronic acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Niiyama Y, Kawamata T, Yamamoto J, Furuse S, Namiki A: SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain. Br J Anaesth; 2009 Feb;102(2):251-8
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: C3H/HeJ mice underwent injection of osteolytic sarcoma cells into the intramedullary space of the femur.
  • The findings of this study may lead to novel strategies for the treatment of bone cancer pain.
  • [MeSH-major] Analgesics / therapeutic use. Anilides / therapeutic use. Bone Neoplasms / complications. Cinnamates / therapeutic use. Pain, Intractable / drug therapy. Sarcoma, Experimental / complications
  • [MeSH-minor] Administration, Oral. Analgesics, Opioid / therapeutic use. Animals. Behavior, Animal / drug effects. Disease Models, Animal. Dose-Response Relationship, Drug. Drug Evaluation, Preclinical / methods. Drug Synergism. Drug Therapy, Combination. Injections, Intraperitoneal. Male. Mice. Mice, Inbred C3H. Morphine / therapeutic use. Neoplasm Transplantation. Pain Measurement / methods. TRPV Cation Channels / antagonists & inhibitors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Anaesth. 2009 Feb;102(2):153-5 [19151045.001]
  • (PMID = 19038965.001).
  • [ISSN] 1471-6771
  • [Journal-full-title] British journal of anaesthesia
  • [ISO-abbreviation] Br J Anaesth
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Analgesics; 0 / Analgesics, Opioid; 0 / Anilides; 0 / Cinnamates; 0 / N-(3-methoxyphenyl)-4-chlorocinnamanilide; 0 / TRPV Cation Channels; 0 / TRPV1 protein, human; 76I7G6D29C / Morphine
  •  go-up   go-down


6. Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, Redini F: Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res; 2010 Oct 1;70(19):7610-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.
  • Ewing's sarcoma (ES) is the second most frequent pediatric bone tumor also arising in soft tissues (15% of cases).
  • The prognosis of patients with clinically detectable metastases at diagnosis, not responding to therapy or with disease relapse, is still very poor.
  • Among new therapeutic approaches, bisphosphonates represent promising adjuvant molecules to chemotherapy to limit the osteolytic component of bone tumors and to protect from bone metastases.
  • ES models were developed to reproduce both soft tissue and intraosseous tumor development.
  • Mice were treated with 100 μg/kg zoledronic acid (two or four times per week) and/or ifosfamide (30 mg/kg, one to three cycles of three injections).
  • Both drugs induced cell cycle arrest, but in the S or G(2)M phase, respectively.
  • In vivo, zoledronic acid had no effect on soft tissue tumor progression, although it dramatically inhibited ES development in bone.
  • When combined with ifosfamide, zoledronic acid exerted synergistic effects in the soft tissue model: Its combination with one cycle of ifosfamide resulted in an inhibitory effect similar to three cycles of ifosfamide alone.
  • This very promising result could allow clinicians to diminish the doses of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Bone Neoplasms / drug therapy. Diphosphonates / pharmacology. Imidazoles / pharmacology. Sarcoma, Ewing / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cyclophosphamide / administration & dosage. Cyclophosphamide / analogs & derivatives. Drug Synergism. Humans. Ifosfamide / administration & dosage. Male. Mice. Mice, Nude


7. Miyata A, Fujii S, Kikuchi T, Kibata M: [Acute myelocytic leukemia (M0) in an elderly patient with relapsed granulocytic sarcoma (M7) of bone during the second period of complete remission 5 years after onset]. Nihon Ronen Igakkai Zasshi; 2003 Mar;40(2):176-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute myelocytic leukemia (M0) in an elderly patient with relapsed granulocytic sarcoma (M7) of bone during the second period of complete remission 5 years after onset].
  • Radiographical bone examination revealed osteolytic lesions in his right knee and bone scintigraphy showed uptake in the right knee and the middle part of the left femur.
  • Histological examination of the biopsied bone tissue showed a diffuse proliferation of round cells with medium-sized or large nuclei.
  • On the basis of these findings we diagnosed these tumors as granulocytic sarcomas (GS), extramedullary recurrence of AML M7.
  • It may be that intensive and repeated chemotherapy for AML can obtain excellent outcome in the elderly cases in good systemic condition and with favourable prognostic factors.
  • [MeSH-major] Bone Neoplasms / pathology. Leukemia, Myeloid, Acute / pathology. Sarcoma, Myeloid / pathology


8. Boumdin H, el Quessar A, Chakir N, el Hassani MR, Jiddane M: [Primary Ewing's sarcoma of the cranial vault. Report of 2 cases]. J Neuroradiol; 2001 Sep;28(3):200-4
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary Ewing's sarcoma of the cranial vault. Report of 2 cases].
  • Primary Ewing sarcoma of the calvarial skull is very rare, found in less than 1% of the cases.
  • We report two cases of primary Ewing sarcoma of the skull (in 13- and 14-year-old boys.
  • The first tumor involved the right temporal region and exhibited unclear osteolytic appearance on skull x-rays while computed tomography showed an extraaxial enhanced mass and bone sclerosis with spiculated periosteal reaction.
  • Plain films demonstrated a large osteolysis and computed tomography revealed extensive bone destruction involving both the inner and outer tables.
  • Adjuvant chemotherapy was given and no recurrence or metastasis has occurred two years later.
  • [MeSH-major] Sarcoma, Ewing / diagnosis. Skull Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11894527.001).
  • [ISSN] 0150-9861
  • [Journal-full-title] Journal of neuroradiology. Journal de neuroradiologie
  • [ISO-abbreviation] J Neuroradiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Ilaslan H, Sundaram M, Unni KK, Dekutoski MB: Primary Ewing's sarcoma of the vertebral column. Skeletal Radiol; 2004 Sep;33(9):506-13
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Ewing's sarcoma of the vertebral column.
  • OBJECTIVE: To determine the demographics, imaging findings, clinical symptoms, and prognosis of primary vertebral Ewing's sarcoma (PVES).
  • Metastatic and soft tissue Ewing's sarcoma cases were excluded.
  • RESULTS: From a total of 1,277 cases of Ewing's sarcoma, 125 (9.8%) had a primary vertebral origin.
  • Satisfactory imaging studies were available in 51 patients: 49 radiographs, 27 computerized tomography (CT), and 23 magnetic resonance imaging (MRI) studies.
  • All patients received radiation in various dosages; 70% additionally received chemotherapy.
  • An aggressive osteolytic lesion, particularly in the sacrum, should raise suspicion for this tumor in adolescents.
  • [MeSH-major] Sacrum / diagnostic imaging. Sarcoma, Ewing / diagnostic imaging. Spinal Neoplasms / diagnostic imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1992 Apr;30(4):610-8; discussion 618-9 [1374853.001]
  • [Cites] J Spinal Disord. 1991 Dec;4(4):480-5 [1810572.001]
  • [Cites] Eur Spine J. 1996;5(6):412-7 [8988385.001]
  • [Cites] Pediatr Radiol. 1992;22(5):388-90 [1408456.001]
  • [Cites] J Can Assoc Radiol. 1976 Dec;27(4):290-7 [993244.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Nov-Dec;20(10):1809-13 [10588101.001]
  • [Cites] Chir Organi Mov. 1998 Jan-Jun;83(1-2):105-11 [9718819.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1981 Jan;7(1):27-31 [7263337.001]
  • [Cites] Med Pediatr Oncol. 2001 Jul;37(1):30-5 [11466720.001]
  • [Cites] Med Pediatr Oncol. 1999 Dec;33(6):594-5 [10573589.001]
  • [Cites] Acta Orthop Scand. 1975 May;46(2):211-5 [1146513.001]
  • [Cites] Skeletal Radiol. 1984;12 (2):69-78 [6484604.001]
  • [Cites] Spine (Phila Pa 1976). 1994 Feb 1;19(3):309-13 [8171362.001]
  • [Cites] J Bone Joint Surg Am. 1975 Jan;57(1):10-6 [1123355.001]
  • [Cites] Med Pediatr Oncol. 1999 Jan;32(1):57-9 [9917755.001]
  • (PMID = 15232658.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Sundaram M, Inwards CY, Shives TE, Anderson PM: Ewing's sarcoma of the humerus mimicking fibrous dysplasia on imaging and biological behavior. Skeletal Radiol; 2005 May;34(5):285-9
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing's sarcoma of the humerus mimicking fibrous dysplasia on imaging and biological behavior.
  • We present the case of a 12-year-old girl who presented with a pathological fracture through a benign-appearing osteolytic lesion that was presumed to represent fibrous dysplasia.
  • A biopsy was performed and revealed Ewing's sarcoma.
  • The disease was locally controlled by neoadjuvant chemotherapy and radiation therapy.
  • [MeSH-major] Bone Neoplasms / diagnostic imaging. Fibrous Dysplasia of Bone / diagnostic imaging. Fractures, Spontaneous / etiology. Humerus / diagnostic imaging. Sarcoma, Ewing / diagnostic imaging
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Radiography

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Genetic Alliance. consumer health - Fibrous Dysplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2000 Oct 1;122(1):30-2 [11104029.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1411-24 [8111708.001]
  • [Cites] Skeletal Radiol. 1997 Dec;26(12 ):722-4 [9453106.001]
  • (PMID = 15838704.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Sato S, Mitsuyama T, Ishii A, Kawakami M, Kawamata T: Multiple primary cranial Ewing's sarcoma in adulthood: case report. Neurosurgery; 2009 Feb;64(2):E384-6; discussion E386
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple primary cranial Ewing's sarcoma in adulthood: case report.
  • OBJECTIVE: Ewing's sarcoma is a malignant bone tumor occurring most frequently in the long bones and flat bones as a solitary lesion during the first 2 decades of life.
  • Ewing's sarcoma and peripheral primitive neuroectodermal tumor have recently been considered to be the same entity because of histological and molecular similarities.
  • A computed tomographic scan revealed osteolytic changes of the inner calvarial bone.
  • Electron microscopy showed little differentiation to neuronal tissue, indicating Ewing's sarcoma.
  • After surgical treatment, conventional whole cranial irradiation of 40 Gy and chemotherapy were conducted.
  • CONCLUSION: Although quite rare, Ewing's sarcoma should be taken into consideration as a differential diagnosis of multiple cranial mass lesions in adulthood.
  • [MeSH-major] Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / therapy. Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / therapy. Skull Neoplasms / diagnosis. Skull Neoplasms / therapy
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190443.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Haresh KP, Chinikkatti SK, Prabhakar R, Rishi A, Rath GK, Sharma DN, Julka PK: A rare case of intradural extramedullary Ewing's sarcoma with skip metastasis in the spine. Spinal Cord; 2008 Aug;46(8):582-4
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of intradural extramedullary Ewing's sarcoma with skip metastasis in the spine.
  • Intradural extramedullary Ewing's sarcoma is extremely rare.
  • PURPOSE: Here, we are reporting a case of intradural extramedullary Ewing's sarcoma.
  • Neither osteolytic nor osteosclerotic changes were seen in the vertebral bodies.
  • Extraskeletal Ewing's sarcoma was diagnosed histopathologically.
  • He was treated by surgery, local radiotherapy and chemotherapy.
  • Two months after treatment, he developed a new skip lesion in the spine at T6-T7 level.
  • The new lesion was treated with local radiotherapy and chemotherapy.
  • RESULTS: Presently, the patient has completed treatment and is clinically doing fine.
  • CONCLUSION: Intradural extramedullary Ewing's sarcoma is a rare aggressive neoplasm with high propensity for skip metastasis.
  • [MeSH-major] Bone Neoplasms / secondary. Sarcoma, Ewing / secondary. Spinal Cord Neoplasms / pathology. Spinal Neoplasms / secondary
  • [MeSH-minor] Adult. Decompression, Surgical / methods. Dura Mater / pathology. Dura Mater / surgery. Humans. Laminectomy / methods. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18268515.001).
  • [ISSN] 1362-4393
  • [Journal-full-title] Spinal cord
  • [ISO-abbreviation] Spinal Cord
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Hoshi S, Satoh M, Ohyama C, Hiramatu M, Watanabe R, Hagisawa S, Endo M, Arai Y: Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma. Int J Clin Oncol; 2003 Apr;8(2):113-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma.
  • There are a few case reports concerning the effectiveness of chemotherapy on metastasis in SRCC.
  • Although, she received continuous infusion of interferon alpha-2a (INFalpha-2a) and interleukin-2 (IL-2) as adjuvant therapy, liver metastasis appeared 2 months later.
  • A computed tomography (CT) scan after the first cycle revealed that the multiple osteolytic bone tumors had significantly decreased in size.
  • A second course of chemotherapy, with gemcitabine and IL-2 was given, but it was ineffective, and the patient died approximately 16 months after the initial diagnosis of SRCC.
  • Combination chemotherapy with gemcitabine, docetaxel, and carboplatin was effective for the bone metastasis of SRCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Carcinoma, Renal Cell / secondary. Deoxycytidine / analogs & derivatives. Kidney Neoplasms / pathology. Paclitaxel / analogs & derivatives. Sarcoma / secondary. Taxoids
  • [MeSH-minor] Adult. Biopsy, Needle. Carboplatin / administration & dosage. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Staging. Nephrectomy / methods. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12720105.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 30
  •  go-up   go-down


14. Rysanek B, Nicolas J, Alix T, Boutard P, Minckes O, Jeanne-Pasquier C, Bénateau H: [Mandibular chloroma]. Rev Stomatol Chir Maxillofac; 2007 Feb;108(1):68-70
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The X-rays showed a fuzzy osteolytic lesion of the mandibular angle.
  • The CT-scan confirmed the rupture of the cortical bone and the extension to the soft tissue.
  • Biopsy provided the diagnosis of granulocytic monoblastic sarcoma (chloroma).
  • Chemotherapy was efficient.
  • Granulocytic monoblastic sarcoma is a localized tumor made of extramedullar immature granulocytes, in general associated (or more rarely preceded by) with leukemia.
  • Early diagnosis is important because high dose chemotherapy induction may completely cure leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mandibular Neoplasms / pathology. Sarcoma, Myeloid / pathology

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17276469.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone; X4W7ZR7023 / Methylprednisolone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


15. Saito O, Aoe T, Yamamoto T: Analgesic effects of nonsteroidal antiinflammatory drugs, acetaminophen, and morphine in a mouse model of bone cancer pain. J Anesth; 2005;19(3):218-24
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analgesic effects of nonsteroidal antiinflammatory drugs, acetaminophen, and morphine in a mouse model of bone cancer pain.
  • To test the analgesic effects of nonsteroidal antiinflammatory drugs on bone cancer pain, the authors examined the effects of oral administration of a cyclooxygenase-1 (COX-1) selective inhibitor (SC560), a COX-2 selective inhibitor (celecoxib), and a nonselective COX inhibitor (indomethacin) on bone cancer pain and compared these effects to the effect of orally administered acetaminophen and morphine.
  • METHODS: An animal model of bone cancer pain was induced by injecting osteolytic murine sarcoma cells in the mouse femur.
  • Drugs were administered orally 2 weeks after tumor-cell implantation, and the level of bone cancer pain was assessed 30, 60, 90, 120, and 180 min after drug administration.
  • [MeSH-major] Acetaminophen / therapeutic use. Analgesics, Non-Narcotic / therapeutic use. Analgesics, Opioid / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Bone Neoplasms / complications. Morphine / therapeutic use. Pain / drug therapy. Pain / etiology. Sarcoma / complications
  • [MeSH-minor] Animals. Bone and Bones / pathology. Cyclooxygenase 1. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Cyclooxygenase Inhibitors / therapeutic use. Dose-Response Relationship, Drug. Drug Therapy, Combination. Male. Membrane Proteins. Mice. Mice, Inbred C3H. Neoplasm Transplantation. Pain Measurement / drug effects. Prostaglandin-Endoperoxide Synthases / metabolism

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Res. 1996 Nov 11;739(1-2):104-10 [8955930.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2005 Apr;288(4):R897-902 [15618346.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7343-9 [12499278.001]
  • [Cites] J Orthop Res. 1996 Jan;14 (1):2-6 [8618161.001]
  • [Cites] Anesth Analg. 2002 Apr;94(4):962-7, table of contents [11916805.001]
  • [Cites] Pain. 1982 Nov;14(3):303-10 [6218464.001]
  • [Cites] Br J Pharmacol. 1973 Sep;49(1):86-97 [4207046.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1998;38:97-120 [9597150.001]
  • [Cites] Nature. 1997 Dec 11;390(6660):611-4 [9403690.001]
  • [Cites] J Orthop Res. 1995 Nov;13(6):892-7 [8544026.001]
  • [Cites] J Neurosci. 1999 Dec 15;19(24):10886-97 [10594070.001]
  • [Cites] Br J Pharmacol. 1998 Apr;123(8):1479-81 [9605550.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31 [12242329.001]
  • [Cites] Pain. 2002 Mar;96(1-2):129-40 [11932069.001]
  • [Cites] J Pharmacol Exp Ther. 2005 May;313(2):668-76 [15650114.001]
  • [Cites] Annu Rev Neurosci. 1984;7:309-38 [6143527.001]
  • [Cites] J Pain Symptom Manage. 1990 Aug;5(4):221-7 [2384701.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3275-80 [10077674.001]
  • [Cites] Pain. 1997 Jan;69(1-2):1-18 [9060007.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13313-8 [9789085.001]
  • [Cites] Pain. 2002 Dec;100(3):219-29 [12467993.001]
  • (PMID = 16032450.001).
  • [ISSN] 0913-8668
  • [Journal-full-title] Journal of anesthesia
  • [ISO-abbreviation] J Anesth
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 0 / Analgesics, Opioid; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Membrane Proteins; 362O9ITL9D / Acetaminophen; 76I7G6D29C / Morphine; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 1.14.99.1 / Ptgs1 protein, mouse
  •  go-up   go-down


16. Luger NM, Honore P, Sabino MA, Schwei MJ, Rogers SD, Mach DB, Clohisy DR, Mantyh PW: Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res; 2001 May 15;61(10):4038-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To begin to define the mechanisms that give rise to advanced bone cancer pain, osteolytic 2472 sarcoma cells or media were injected into the intramedullary space of the femur of C3H/HeJ mice, and the injection hole was sealed using dental amalgam, confining the tumor cells to the bone.
  • Results indicated that osteoprotegerin treatment halted further bone destruction, reduced ongoing and movement-evoked pain, and reversed several aspects of the neurochemical reorganization of the spinal cord.
  • [MeSH-major] Bone Neoplasms / complications. Glycoproteins / pharmacology. Pain / drug therapy
  • [MeSH-minor] Animals. Disease Models, Animal. Male. Mice. Mice, Inbred C3H. Neurons, Afferent / metabolism. Neurons, Afferent / physiology. Osteoclasts / drug effects. Osteoclasts / physiology. Osteolysis / complications. Osteolysis / drug therapy. Osteolysis / etiology. Osteoprotegerin. Proto-Oncogene Proteins c-fos / biosynthesis. Receptors, Cytoplasmic and Nuclear. Receptors, Tumor Necrosis Factor. Sarcoma, Experimental / complications. Sarcoma, Experimental / pathology. Spinal Cord / drug effects. Spinal Cord / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11358823.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR43595; United States / NIDA NIH HHS / DA / DA11986; United States / NIDCR NIH HHS / DE / DE00270; United States / NIDCR NIH HHS / DE / DE07288; United States / NINDS NIH HHS / NS / NS23970
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Osteoprotegerin; 0 / Proto-Oncogene Proteins c-fos; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Tumor Necrosis Factor; 0 / Tnfrsf11b protein, mouse
  •  go-up   go-down


17. Warda E, Mazurkiewicz T, Kopacz J, Gronowska S: Advances in musculoskeletal oncology: experience of the Lublin Orthopedic Clinic. Ortop Traumatol Rehabil; 2004 Oct 30;6(5):685-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Major milestones in the diagnosis and treatment of musculoskeletal tumors and tumor-like lesions are presented on the basis of the authors' 40 years of experience in the Lublin Orthopedic Clinic.
  • Great progress has also been observed in treatment methods.
  • Burring of sclerotic bony walls in benign osteolytic lesions is a major improvement over traditional but ineffective curettage.
  • A multidisciplinary approach using neoadjuvant chemotherapy has radically improved outcomes in the treatment of ostegenic sarcoma and Ewing's sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17618220.001).
  • [ISSN] 1509-3492
  • [Journal-full-title] Ortopedia, traumatologia, rehabilitacja
  • [ISO-abbreviation] Ortop Traumatol Rehabil
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


18. Delépine F, Delépine G, Belarbi L, Markowska B, Alkallaf S, Cornille H, Delépine N: [Diagnosis and treatment of malignant bone fibrohistiocytoma]. Ann Med Interne (Paris); 2001 Nov;152(7):437-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of malignant bone fibrohistiocytoma].
  • [Transliterated title] Diagnostic et traitement des histiocytofibromes malins de l'os.
  • Malignant fibrous histiocytoma (MFH) and giant cells sarcoma arise from fibrous tissue and histiocytic cells evenly distributed in all age group, except children much less common than osteosarcoma and chondrosarcoma.
  • Medical imaging shows a purely osteolytic tumor centrally or eccentrically located, ill defined with a permeative or even moth eaten patterns.
  • Outcome was historically better than those of osteosarcoma but hangs on the grading of tumors; low grade sarcoma have a regional evolution while high grade malignant histiocytofibroma are threatened with metastases.
  • Therapy must be adapted to the histological grading and the extent of the illness.
  • High grade MFH are preferentially treated by a comprehensive multidisciplinary approach with preoperative chemotherapy including high dose methotrexate, wide resection and postoperative chemotherapy.
  • With such a treatment, nearly 80% of patients seen with localized tumor of the limb can be cured and keep a functional limb.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Female. Humans. Limb Salvage. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11965084.001).
  • [ISSN] 0003-410X
  • [Journal-full-title] Annales de médecine interne
  • [ISO-abbreviation] Ann Med Interne (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. Lipton A, Campbell-Baird C, Harvey H, Kim C, Demers L, Costa L: Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases. Am J Clin Oncol; 2010 Feb;33(1):75-8
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment consists of radiation or surgery to prevent or repair fractures and bisphosphonates to delay skeletal-related events (SRE).
  • This phase I study assessed the effects of the combination of zoledronic acid (a bisphosphonate used to delay SRE) and Gleevec on 15 evaluable patients with osteolytic or osteoblastic bone metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Breast Neoplasms / drug therapy. Kidney Neoplasms / drug therapy. Prostatic Neoplasms / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Aged. Benzamides. Diphosphonates / administration & dosage. Female. Humans. Imatinib Mesylate. Imidazoles / administration & dosage. Male. Maximum Tolerated Dose. Neoplasm Staging. Piperazines / administration & dosage. Prognosis. Pyrimidines / administration & dosage. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652577.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Diphosphonates; 0 / Imidazoles; 0 / Piperazines; 0 / Pyrimidines; 6XC1PAD3KF / zoledronic acid; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


20. Okada K, Hasegawa T, Nishida J, Ogose A, Tajino T, Osanai T, Yanagisawa M, Hatori M: Osteosarcomas after the age of 50: a clinicopathologic study of 64 cases--an experience in northern Japan. Ann Surg Oncol; 2004 Nov;11(11):998-1004
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common location was the distal femur (n = 13), followed by the pelvis (n = 10), proximal femur (n = 9), and proximal fibula (n = 6).
  • On radiographs, an osteolytic appearance without periosteal reactions was a common and characteristic feature.
  • Fourteen cases (22%) were secondary; postradiation osteosarcoma was most common in these patients, but there was no Paget's sarcoma.
  • Preoperative chemotherapy was given to 22 patients, but the effect was poor in 18 cases (82%).
  • Current systemic chemotherapy is not effective for this age group.
  • Alternative treatment strategies should be considered.
  • [MeSH-minor] Age of Onset. Aged. Combined Modality Therapy. Female. Humans. Japan. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Metastasis. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15525829.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Hamidah NH, Azma RZ, Ezalia E, Das S, Umar NA, Swaminathan M, Mohamed Z, Abdul Wahid SF: Non-secretory multiple myeloma with diagnostic challenges. Clin Ter; 2010;161(5):445-8
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a 71-year-old man who had been diagnosed and treated for granulocytic sarcoma one year prior to his recent problems of progressive low-back pain of two months duration.
  • Skeletal X-rays showed diffuse osteolytic lesions with multiple pathological fractures but there was no monoclonal gammopathy in the serum or urine.
  • A diagnosis of NSMM was made and he was treated with chemotherapy.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20949241.001).
  • [ISSN] 1972-6007
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


22. Sevcik MA, Luger NM, Mach DB, Sabino MA, Peters CM, Ghilardi JR, Schwei MJ, Röhrich H, De Felipe C, Kuskowski MA, Mantyh PW: Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. Pain; 2004 Sep;111(1-2):169-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Following injection and confinement of green fluorescent protein-transfected murine osteolytic tumor cells into the marrow space of the femur of male C3H/HeJ mice, alendronate was administered chronically from the time the tumor was established until the bone cancer pain became severe.
  • Alendronate therapy reduced ongoing and movement-evoked bone cancer pain, bone destruction and the destruction of sensory nerve fibers that innervate the bone.
  • Whereas, alendronate treatment did not change viable tumor burden, both tumor growth and tumor necrosis increased.
  • [MeSH-major] Alendronate / pharmacology. Bone Neoplasms / drug therapy. Osteolysis / drug therapy. Pain / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Activating Transcription Factor 3. Animals. Behavior, Animal. Biomarkers, Tumor. Male. Mice. Mice, Inbred C3H. Necrosis. Osteoclasts / drug effects. Osteoclasts / pathology. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Alendronic acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15327821.001).
  • [ISSN] 0304-3959
  • [Journal-full-title] Pain
  • [ISO-abbreviation] Pain
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / 1F30-DE01471-01A1; United States / NIDCR NIH HHS / DE / 5 K16 DE00270-12; United States / NIDA NIH HHS / DA / DA11986; United States / NINDS NIH HHS / NS / NS23970
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Activating Transcription Factor 3; 0 / Biomarkers, Tumor; 0 / Transcription Factors; X1J18R4W8P / Alendronate
  •  go-up   go-down


23. Kurth AA, Kim SZ, Sedlmeyer I, Bauss F, Shea M: Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat. Bone; 2002 Jan;30(1):300-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat.
  • Bisphosphonate treatment is beneficial against symptoms of metastatic bone disease, although less is known about the effect of preventative treatment schedules.
  • We investigated the effect of various treatment regimens of the bisphosphonate, ibandronate (IB), on the preservation of bone quality in a rat model of tumor-induced osteolysis.
  • Osteolytic Walker 256 (W256) carcinosarcoma cells were implanted into the left femur of female Sprague-Dawley rats, resulting in a 10% reduction in bone mineral density (BMD), a 16% reduction in bone density (BD), and a 26% reduction in failure load compared with the right femur 28 days after implantation.
  • IB was administered subcutaneously in five different treatment schedules:.
  • (4) IB PRE-0 received IB injections for 26 days and was then killed to serve as a time zero control; and (5) IB POST received sham injection with saline before W256 cell insertion, and then received IB injections for 28 days until killing.
  • We used dual-energy X-ray absorptiometry (DXA) to measure distal femur BMD and bone mineral content (BMC), peripheral quantitative computed tomography (pQCT) to measure distal femur BD, and torsion testing to obtain torsional failure load.
  • Combined preventative and interventional IB treatment best preserved bone mass and strength, although all treatment schedules resulted in significant improvement compared with untreated controls (TUMOR ONLY).
  • [MeSH-major] Bone Density / drug effects. Bone Neoplasms / drug therapy. Bone Neoplasms / physiopathology. Diphosphonates / therapeutic use. Sarcoma, Experimental / drug therapy. Sarcoma, Experimental / physiopathology
  • [MeSH-minor] Animals. Biomechanical Phenomena. Female. Fractures, Bone / prevention & control. Humans. Mammary Neoplasms, Experimental / complications. Mammary Neoplasms, Experimental / drug therapy. Mammary Neoplasms, Experimental / physiopathology. Osteolysis / drug therapy. Osteolysis / etiology. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11792601.001).
  • [ISSN] 8756-3282
  • [Journal-full-title] Bone
  • [ISO-abbreviation] Bone
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 114084-78-5 / ibandronic acid
  •  go-up   go-down


24. Singer FR: Paget disease: when to treat and when not to treat. Nat Rev Rheumatol; 2009 Sep;5(9):483-9
MedlinePlus Health Information. consumer health - Paget's Disease of Bone.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients are often asymptomatic, but a subset experience considerable morbidity that can include bone pain and skeletal deformity, as well as a variety of regional complications, such as hearing loss associated with cranial involvement, degenerative arthritis of the hip or knee, fractures of the lower extremities and, rarely, sarcoma or giant cell tumors.
  • Administration of these agents can relieve bone pain, decrease biochemical markers of bone resorption and bone formation, and retard or reverse the early osteolytic phase of the disease.
  • Future studies are needed to determine whether these drugs, if used in an early stage of the disease, can prevent complications in asymptomatic patients.
  • [MeSH-major] Diphosphonates / therapeutic use. Osteitis Deformans / drug therapy
  • [MeSH-minor] Bone Density Conservation Agents / therapeutic use. Humans. Incidental Findings. Osteoclasts / drug effects. Osteogenesis / drug effects. Osteolysis / drug therapy. Pain / prevention & control

  • Genetic Alliance. consumer health - Paget Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652650.001).
  • [ISSN] 1759-4804
  • [Journal-full-title] Nature reviews. Rheumatology
  • [ISO-abbreviation] Nat Rev Rheumatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates
  • [Number-of-references] 71
  •  go-up   go-down


25. Döll C, Wulff B, Rössler J, Schaper J, Havers W: Primary B-cell lymphoma of bone in children. Eur J Pediatr; 2001 Apr;160(4):239-42
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on two children with PLB focussing on diagnostic evaluation and treatment strategy.
  • Clinical and radiographic presentation in both children suggested a primary bone tumour such as Ewing sarcoma.
  • A 13-year-old girl showed osteolytic tumours in the right 7th rib and right iliac crest.
  • Additional skeletal lesions were found by whole-body positron emission tomography.
  • A 6-year-old boy presented with an isolated, osteolytic lesion of the left distal femur.
  • Multiple therapeutic strategies have been applied in the treatment of this malignancy, however, treatment modalities are not well focussed on immunological patterns in the case of primary lymphoma of bone.
  • Staging techniques should include immunophenotyping to initiate specific cell lineage treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / diagnosis. Bone Neoplasms / drug therapy. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11317647.001).
  • [ISSN] 0340-6199
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Sabino MA, Ghilardi JR, Jongen JL, Keyser CP, Luger NM, Mach DB, Peters CM, Rogers SD, Schwei MJ, de Felipe C, Mantyh PW: Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res; 2002 Dec 15;62(24):7343-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several tumor types including sarcomas and breast, prostate, and lung carcinomas grow in or preferentially metastasize to the skeleton where they proliferate, and induce significant bone remodeling, bone destruction, and cancer pain.
  • To begin to define the role COX-2 plays in driving bone cancer pain, we used an in vivo model where murine osteolytic 2472 sarcoma cells were injected and confined to the intramedullary space of the femur in male C3HHeJ mice.
  • [MeSH-major] Bone Neoplasms / complications. Bone Neoplasms / drug therapy. Cyclooxygenase Inhibitors / pharmacology. Isoenzymes / antagonists & inhibitors. Osteosarcoma / complications. Osteosarcoma / drug therapy. Pain / drug therapy
  • [MeSH-minor] Animals. Cell Division / drug effects. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Disease Models, Animal. Hyperostosis / drug therapy. Hyperostosis / enzymology. Hyperostosis / pathology. Male. Mice. Mice, Inbred C3H. Neurons, Afferent / drug effects. Neurons, Afferent / physiology. Osteoclasts / cytology. Osteoclasts / drug effects. Osteoclasts / pathology. Prostaglandin-Endoperoxide Synthases. Spinal Cord / drug effects. Spinal Cord / physiopathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12499278.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA11986; United States / NIDCR NIH HHS / DE / DE00270; United States / NIDCR NIH HHS / DE / DE07288; United States / NINDS NIH HHS / NS / NS23970
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


27. Halvorson KG, Sevcik MA, Ghilardi JR, Sullivan LJ, Koewler NJ, Bauss F, Mantyh PW: Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer. J Pain Symptom Manage; 2008 Sep;36(3):289-303
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Currently, bone pain is treated primarily by opioid-based therapies, which are frequently accompanied by significant unwanted side effects.
  • In an effort to develop nonopioid-based therapies that could rapidly attenuate tumor-induced bone pain, we examined the effect of intravenous administration of the bisphosphonate, ibandronate, in a mouse model of bone cancer pain.
  • Following injection and confinement of green fluorescent protein-transfected murine osteolytic 2472 sarcoma cells into the marrow space of the femur of male C3H/HeJ mice, ibandronate was administered either as a single dose (300 microg/kg), at Day 7 post-tumor injection, when tumor-induced bone destruction and pain were first evident, or in three consecutive doses (100 microg/kg/day) at Days 7, 8, and 9 post-tumor injection.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuron. 1998 Sep;21(3):531-43 [9768840.001]
  • [Cites] J Bone Miner Res. 1998 Nov;13(11):1721-9 [9797481.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5294-7 [9850051.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1082-90 [10699899.001]
  • [Cites] Cell Tissue Res. 2000 Feb;299(2):193-200 [10741460.001]
  • [Cites] Ann Clin Biochem. 2001 Nov;38(Pt 6):608-23 [11732644.001]
  • [Cites] Calcif Tissue Int. 2002 Jan;70(1):40-7 [11907706.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2708-14 [11980672.001]
  • [Cites] Neuroscience. 2002;113(1):155-66 [12123694.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Sep;302(3):1055-61 [12183663.001]
  • [Cites] Cancer Treat Rev. 1998 Dec;24(6):425-32 [10189409.001]
  • [Cites] Lancet. 1999 May 15;353(9165):1695-700 [10335806.001]
  • [Cites] Oncology (Williston Park). 1999 May;13(5 Suppl 2):25-9 [10356695.001]
  • [Cites] J Bone Miner Res. 1999 Oct;14(10):1768-78 [10491225.001]
  • [Cites] Pain. 2005 May;115(1-2):128-41 [15836976.001]
  • [Cites] Support Care Cancer. 2006 May;14(5):408-18 [16450087.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2862-8 [16675582.001]
  • [Cites] Nat Neurosci. 2006 Dec;9(12):1534-40 [17115041.001]
  • [Cites] Bone. 2007 Mar;40(3):645-55 [17174621.001]
  • [Cites] J Neurosci. 1999 Dec 15;19(24):10886-97 [10594070.001]
  • [Cites] Pain. 2002 Oct;99(3):397-406 [12406514.001]
  • [Cites] J Rheumatol. 2002 Oct;29(10):2200-8 [12375334.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6538-44 [12438248.001]
  • [Cites] Pain. 2002 Dec;100(3):219-29 [12467993.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7343-9 [12499278.001]
  • [Cites] Bone. 2003 Jan;32(1):45-55 [12584035.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):550-8 [12594809.001]
  • [Cites] Eur J Pharm Sci. 2003 Jul;19(4):223-30 [12885386.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):468-77 [14506749.001]
  • [Cites] Palliat Med. 2003 Sep;17(6):539-53 [14526888.001]
  • [Cites] Curr Pharm Des. 2003;9(32):2643-58 [14529538.001]
  • [Cites] Pain. 2000 May;86(1-2):185-94 [10779675.001]
  • [Cites] Nat Med. 2000 May;6(5):521-8 [10802707.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2949-54 [10850442.001]
  • [Cites] Neuroscience. 2000;98(3):585-98 [10869852.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):2961-78 [10898340.001]
  • [Cites] Ann N Y Acad Sci. 2000;909:12-24 [10911921.001]
  • [Cites] Anat Rec. 2000 Oct 1;260(2):180-8 [10993954.001]
  • [Cites] J Bone Miner Res. 2000 Nov;15(11):2211-21 [11092402.001]
  • [Cites] Prog Brain Res. 2000;129:389-97 [11098706.001]
  • [Cites] J Neurosci. 2001 Mar 1;21(5):1779-86 [11222667.001]
  • [Cites] Pain. 2001 May;92(1-2):5-9 [11323121.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4038-47 [11358823.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4418-24 [11389070.001]
  • [Cites] Osteoporos Int. 2004 Jun;15(6):423-33 [15205712.001]
  • [Cites] J Clin Pharmacol. 2004 Sep;44(9):951-65 [15317823.001]
  • [Cites] Pain. 2004 Sep;111(1-2):169-80 [15327821.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5 Suppl 10):67-72 [15490379.001]
  • [Cites] Biochim Biophys Acta. 1986 Aug 5;865(1):27-41 [3524684.001]
  • [Cites] J Comp Neurol. 1987 Jun 8;260(2):246-55 [3038969.001]
  • [Cites] Nature. 1987 Aug 13-19;328(6131):632-4 [3112583.001]
  • [Cites] Brain Res. 1988 Jul 12;455(2):205-12 [2900057.001]
  • [Cites] J Clin Invest. 1989 Jun;83(6):1930-5 [2524504.001]
  • [Cites] J Bone Miner Res. 1990 Jan;5(1):31-40 [2106763.001]
  • [Cites] Pain. 1990 Jun;41(3):273-81 [1697056.001]
  • [Cites] Brain Res Mol Brain Res. 1991 Jun;10(3):227-33 [1679515.001]
  • [Cites] J Bone Miner Res. 1991 Sep;6(9):1003-11 [1838661.001]
  • [Cites] Clin Orthop Relat Res. 1995 Mar;(312):19-33 [7634602.001]
  • [Cites] Neurology. 1995 Oct;45(10):1848-55 [7477980.001]
  • [Cites] Pharmacol Toxicol. 1996 Jul;79(1):40-6 [8841095.001]
  • [Cites] Bone. 1996 Sep;19(3):281-90 [8873969.001]
  • [Cites] Pain. 1996 Dec;68(2-3):275-81 [9121815.001]
  • [Cites] Pain. 1997 Jan;69(1-2):1-18 [9060007.001]
  • [Cites] Nature. 1997 Mar 13;386(6621):173-7 [9062189.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):816-24 [9349813.001]
  • [Cites] J Biol Chem. 1997 Nov 14;272(46):28819-22 [9360943.001]
  • [Cites] J Bone Miner Res. 1998 Apr;13(4):581-9 [9556058.001]
  • [Cites] Neuroreport. 1998 Apr 20;9(6):1109-13 [9601677.001]
  • [Cites] Neurosci Lett. 1998 Jul 31;251(3):169-72 [9726370.001]
  • (PMID = 18411018.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS023970-20; United States / NINDS NIH HHS / NS / R37 NS023970; United States / NINDS NIH HHS / NS / NS048021-04; United States / NINDS NIH HHS / NS / R01 NS048021; United States / NINDS NIH HHS / NS / NS048021; United States / NINDS NIH HHS / NS / NS23970; United States / NINDS NIH HHS / NS / R01 NS048021-04; United States / NINDS NIH HHS / NS / R01 NS023970; United States / NINDS NIH HHS / NS / R37 NS023970-20
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 114084-78-5 / ibandronic acid
  • [Other-IDs] NLM/ NIHMS68973; NLM/ PMC2638081
  •  go-up   go-down






Advertisement